Relationship of Phospholipid Transfer Protein Activity to HDL and Apolipoprotein B-Containing Lipoproteins in Subjects With and Without Type 1 Diabetes
Relationship of Phospholipid Transfer Protein Activity to HDL and Apolipoprotein B-Containing Lipoproteins in Subjects With and Without Type 1 Diabetes Helen M. Colhoun 1 , Marja-Riitta Taskinen 2 , James D. Otvos 3 , Paul van den Berg 4 , John O’Connor 2 and Arie Van Tol 4 1 Royal Free and Universi...
Gespeichert in:
Veröffentlicht in: | Diabetes (New York, N.Y.) N.Y.), 2002-11, Vol.51 (11), p.3300-3305 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Relationship of Phospholipid Transfer Protein Activity to HDL and Apolipoprotein B-Containing Lipoproteins in Subjects With
and Without Type 1 Diabetes
Helen M. Colhoun 1 ,
Marja-Riitta Taskinen 2 ,
James D. Otvos 3 ,
Paul van den Berg 4 ,
John O’Connor 2 and
Arie Van Tol 4
1 Royal Free and University College London Medical School, London, U.K.
2 University of Helsinki Hospital, Helsinki, Finland
3 Liposcience Inc., Raleigh, North Carolina
4 Department of Biochemistry, Cardiovascular Research Institute COEUR, Erasmus University, Rotterdam, the Netherlands
Abstract
Patients with type 1 diabetes have greatly increased phospholipid transfer protein (PLTP) activity and have an altered HDL
subclass distribution. In 195 patients with type 1 diabetes and in 194 men and women aged 30–55 years, we examined the relationship
of PLTP activity to HDL and examined whether PLTP activity contributes to differences in HDL found in type 1 diabetes. PLTP
activity was measured using an exogenous substrate assay. Average HDL particle size and HDL subclasses were measured using
nuclear magnetic resonance spectroscopy. Apolipoprotein AI (apoAI) and apoAII were measured by immunoturbidimetry. The amount
of apoAI present in LpAI was measured using a differential electroimmunoassay, and the amount of apoAI in LpAIAII was inferred
from the apoAI and LpAI data. Higher PLTP activity was associated with more large HDL ( P < 0.001) and less small HDL ( P < 0.01), more apoAI and apoAII (both at P < 0.001), and more apoAI in both LpAI and LpAIAII ( P = 0.02 and P < 0.001, respectively). These associations were independent of other lipids and enzyme activities. Adjusting for PLTP activity
halved the difference between subjects with and without diabetes in apoA1 (from 10.1 mg/dl higher in subjects with diabetes
to 4.6 mg/dl higher) and large HDL (2.4 μmol/l higher to 1.2 μmol/l higher) and reduced the difference in HDL size (from 0.31
nm higher to 0.26 nm higher). PLTP activity was also positively associated with apoB, total VLDL and LDL particle number,
and IDL level in subjects with diabetes. These data support the idea that PLTP is a major factor in HDL conversion and remodeling
in humans and that higher PLTP activity makes an important contribution to the higher apoAI levels and altered HDL subclass
distribution in type 1 diabetes. They also support a role for PLTP in the metabolism of apoB-containing lipoproteins.
Footnotes
Address correspondence and reprint requests to Helen M. Colhou |
---|---|
ISSN: | 0012-1797 1939-327X |
DOI: | 10.2337/diabetes.51.11.3300 |